Antihyperuricemic Effect of Urolithin A in Cultured Hepatocytes and Model Mice
1
Center for Bioscience Research and Education, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan
2
Alliance for Research on the Mediterranean and North Africa (ARENA), University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8572, Ibaraki, Japan
3
Interdisciplinary Research Center for Catalytic Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba 305-8565, Ibaraki, Japan
4
Laboratory of International Environmental Health, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan
5
Faculty of Agriculture, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan
6
Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba 305-8572, Ibaraki, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Derek J. McPhee
Molecules 2020, 25(21), 5136; https://doi.org/10.3390/molecules25215136
Received: 30 September 2020 / Revised: 28 October 2020 / Accepted: 31 October 2020 / Published: 4 November 2020
(This article belongs to the Special Issue Polyphenol and Its Related Compounds: Bioactivity and Molecular Mechanism)
Hyperuricemia is defined as a disease with high uric acid (UA) levels in the blood and a strong risk factor for gout. Urolithin A (UroA) is a main microbial metabolite derived from ellagic acid (EA), which occurs in strawberries and pomegranates. In this study, we evaluated antihyperuricemic effect of UroA in both cultured hepatocytes and hyperuricemic model mice. In cultured hepatocytes, UroA significantly and dose-dependently reduced UA production. In model mice with purine bodies-induced hyperuricemia, oral administration of UroA significantly inhibited the increase in plasma UA levels and hepatic xanthine oxidase (XO) activity. In addition, DNA microarray results exhibited that UroA, as well as allopurinol, a strong XO inhibitor, induced downregulation of the expression of genes associated with hepatic purine metabolism. Thus, hypouricemic effect of UroA could be, at least partly, attributed to inhibition of purine metabolism and UA production by suppressing XO activity in the liver. These results indicate UroA possesses a potent antihyperuricemic effect and it could be a potential candidate for a molecule capable of preventing and improving hyperuricemia and gout.
View Full-Text
Keywords:
urolithin A; ellagic acid; AML12 hepatocyte; hyperuricemia; uric acid
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Adachi, S.-i.; Sasaki, K.; Kondo, S.; Komatsu, W.; Yoshizawa, F.; Isoda, H.; Yagasaki, K. Antihyperuricemic Effect of Urolithin A in Cultured Hepatocytes and Model Mice. Molecules 2020, 25, 5136. https://doi.org/10.3390/molecules25215136
AMA Style
Adachi S-i, Sasaki K, Kondo S, Komatsu W, Yoshizawa F, Isoda H, Yagasaki K. Antihyperuricemic Effect of Urolithin A in Cultured Hepatocytes and Model Mice. Molecules. 2020; 25(21):5136. https://doi.org/10.3390/molecules25215136
Chicago/Turabian StyleAdachi, Shin-ichi; Sasaki, Kazunori; Kondo, Shinji; Komatsu, Wataru; Yoshizawa, Fumiaki; Isoda, Hiroko; Yagasaki, Kazumi. 2020. "Antihyperuricemic Effect of Urolithin A in Cultured Hepatocytes and Model Mice" Molecules 25, no. 21: 5136. https://doi.org/10.3390/molecules25215136
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit


